|
News for: |
|
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
FDA Approval Activities for this Drug…
Camptosar (irinotecan HCl injection), Pharmacia & Upjohn Co. NDA 20-571/S-016 5/16/02 5/21/02 5/16/02 Camptosar (irinotecan hydrochlorise injection)20 mg/mL Intravenous, Pharmacia & Upjohn NDA 20-571/S-008 10/22/98 10/26/98 10/26/98 7/21/99 Camptosar: Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Camptosar Injection (irinotecan hydrochloride injection), . Pharmacia & Upjohn NDA 20-571/S-009 4/20/00 4/24/00 4/24/00 6/4/01 Camptosar Indication: A component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR Injection (irinotecan hydrochloride), Pfizer | CAMPTOSAR (irinotecan hydrochloride) Injection, Pfizer, Labeling Revision | CAMPTOSAR (irinotecan hydrochloride) injection, Pfizer, Labeling Revision | Camptosar (irinotecan hydrochloride) injection, Pfizer, Inc., Labeling Revisions | Camptosar (Irinotecan Hydrochloride) Injection, Pfizer, Labeling Revision | Camptosar (Irinotecan Hydrochloride) Injection, Pfizer, Inc., Labeling Revision
|